3.65
-0.175(-4.58%)
Currency In USD
| Previous Close | 3.82 |
| Open | 3.79 |
| Day High | 3.83 |
| Day Low | 3.63 |
| 52-Week High | 4.08 |
| 52-Week Low | 1.27 |
| Volume | 914,935 |
| Average Volume | 1.16M |
| Market Cap | 504.05M |
| PE | -7.92 |
| EPS | -0.46 |
| Moving Average 50 Days | 3.24 |
| Moving Average 200 Days | 2.54 |
| Change | -0.18 |
If you invested $1000 in Compass Therapeutics, Inc. (CMPX) since IPO date, it would be worth $428.82 as of September 30, 2025 at a share price of $3.645. Whereas If you bought $1000 worth of Compass Therapeutics, Inc. (CMPX) shares 3 years ago, it would be worth $1,598.68 as of September 30, 2025 at a share price of $3.645.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Compass Therapeutics to Participate in Upcoming September Investor Events
GlobeNewswire Inc.
Aug 26, 2025 12:00 PM GMT
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
GlobeNewswire Inc.
Aug 13, 2025 2:28 AM GMT
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today
Compass Therapeutics Announces Proposed Public Offering
GlobeNewswire Inc.
Aug 12, 2025 8:01 PM GMT
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today